` 3933 (United Laboratories International Holdings Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

3933
vs
Hang Seng (Hong Kong)

Over the past 12 months, has outperformed Hang Seng (Hong Kong), delivering a return of 53% compared to the Hang Seng (Hong Kong)'s 37% growth.

Stocks Performance
3933 vs Hang Seng (Hong Kong)

Loading

Performance Gap
3933 vs Hang Seng (Hong Kong)

Loading
3933
Hang Seng (Hong Kong)
Difference

Performance By Year
3933 vs Hang Seng (Hong Kong)

Loading
3933
Hang Seng (Hong Kong)
Add Stock

Competitors Performance
United Laboratories International Holdings Ltd vs Peers

Hang Seng (Hong Kong)
3933
LLY
JNJ
NOVO B
ROG
Add Stock

United Laboratories International Holdings Ltd
Glance View

Economic Moat
Narrow
Market Cap
26.6B HKD
Industry
Pharmaceuticals

United Laboratories International Holdings Ltd. has carved a significant niche in the global pharmaceutical industry, primarily through its prowess in producing antibiotic finished products and intermediates. Headquartered in Hong Kong, the company operates a diversified business model that spans manufacturing, marketing, and distribution of a wide range of pharmaceutical products. United Laboratories has established robust production facilities in China, positioning itself as one of the leading producers of antibiotics like amoxicillin and ampicillin. These products are vital to combating infections and are critical components in healthcare systems worldwide. The company's vertically integrated operations, coupled with its strategic focus on research and development, enable it to maintain cost efficiency while innovating continuously within its drug portfolio. The company's revenue mechanism is firmly rooted in its extensive distribution network and expansive market reach, which traverse not only the domestic markets but also international territories in North America, Europe, and Asia. United Laboratories leverages its strong brand presence and economies of scale to offer competitive pricing, enhancing its market penetration. Furthermore, it capitalizes on favorable regulatory frameworks in emerging markets, creating a tapestry of growth opportunities. The company's business strategy is also marked by its commitment to quality and adherence to stringent production standards, essential for maintaining trust and reliability among healthcare providers. Through these strategic channels, United Laboratories International Holdings Ltd. sustains its growth and profitability in the dynamic pharmaceutical landscape.

Intrinsic Value
20.6 HKD
Undervaluation 29%
Intrinsic Value
Price
U
Back to Top